Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, posted on X:
“As a myeloma physician, I prescribed $6.8 million worth of lenalidomide and pomalidomide through Medicare Part D in 2022.
This staggering figure reflects just one piece of the financial weight myeloma places on patients and the healthcare system. Behind every dollar is a patient fighting for more time, better quality of life, and hope.”